CY1120239T1 - Συνθετικα μιμητικα απελινης για την θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας - Google Patents
Συνθετικα μιμητικα απελινης για την θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειαςInfo
- Publication number
- CY1120239T1 CY1120239T1 CY20181100556T CY181100556T CY1120239T1 CY 1120239 T1 CY1120239 T1 CY 1120239T1 CY 20181100556 T CY20181100556 T CY 20181100556T CY 181100556 T CY181100556 T CY 181100556T CY 1120239 T1 CY1120239 T1 CY 1120239T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- heart failure
- myocardial infarction
- mimmetics
- therapeutic treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Abstract
Η εφεύρεση παρέχει ένα συνθετικό πολυπεπτίδιο του τύπου Ι', ή ένα αμίδιο, έναν εστέρα ή ένα άλας αυτού, όπου τα XI, Χ2, Χ3, Χ4, Χ5, Χ6, Χ7, Χ8, Χ9, Χ10, X11, Χ12 και Χ13 έχουν όπως ορίζεται στην παρούσα. Τα πολυπεπτίδια είναι αγωνιστές του υποδοχέα APJ. Η εφεύρεση αφορά επίσης σε μια μέθοδο παρασκευής των πολυπεπτιδίων της εφεύρεσης και στις θεραπευτικές της χρήσεις όπως ως θεραπευτική αντιμετώπιση ή πρόληψη της οξείας μη αντιρροπούμενης καρδιακής ανεπάρκειας (ADHF), της χρόνιας καρδιακής ανεπάρκειας, της πνευμονικής υπέρτασης, της κολπικής μαρμαρυγής, του συνδρόμου Brugada, της κοιλιακής ταχυκαρδίας, της αθηροσκλήρωσης, της υπέρτασης, της επαναστένωσης, των ισχαιμικών καρδιαγγειακών νοσημάτων, της καρδιομυοπάθειας, της καρδιακής ίνωσης, της αρρυθμίας, της κατακράτησης ύδατος, του διαβήτη (συμπεριλαμβανομένου του διαβήτη εγκυμοσύνης), της παχυσαρκίας, της περιφερικής αρτηριακής νόσου, των αγγειακών εγκεφαλικών επεισοδίων, των παροδικών ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων, των τραυματικών εγκεφαλικών κακώσεων, της πλάγιας μυατροφικής σκλήρυνσης, των εγκαυμάτων (συμπεριλαμβανομένου του εγκαύματος από ηλιακή ακτινοβολία) και της προεκλαμψίας. Η παρούσα εφεύρεση παρέχει περαιτέρω έναν συνδυασμό φαρμακολογικώς δραστικών παραγόντων και μια φαρμακευτική σύνθεση.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591557P | 2012-01-27 | 2012-01-27 | |
US201261717760P | 2012-10-24 | 2012-10-24 | |
US201261731697P | 2012-11-30 | 2012-11-30 | |
PCT/IB2013/050666 WO2013111110A2 (en) | 2012-01-27 | 2013-01-25 | Synthetic apelin mimetics for the treatment of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120239T1 true CY1120239T1 (el) | 2019-07-10 |
Family
ID=47997598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100556T CY1120239T1 (el) | 2012-01-27 | 2018-05-24 | Συνθετικα μιμητικα απελινης για την θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας |
Country Status (43)
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
CN113007106B (zh) | 2011-07-13 | 2023-08-11 | 费雪派克医疗保健有限公司 | 叶轮和马达组件 |
US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
US10022256B2 (en) * | 2012-11-30 | 2018-07-17 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
CN205515844U (zh) | 2012-12-18 | 2016-08-31 | 费雪派克医疗保健有限公司 | 呼吸辅助装置以及用于电机的总成 |
EP2935311B1 (en) * | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
BR112015020587A2 (pt) * | 2013-03-14 | 2017-10-10 | Regeneron Pharma | proteínas de fusão de apelina e suas utilizações |
AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
JP6505692B2 (ja) * | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
SG11201600208RA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
EP3024846A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
CA2931299C (en) | 2013-11-20 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
EA201691075A1 (ru) * | 2013-11-26 | 2016-09-30 | Новартис Аг | Способы оксимной конъюгации с кетон-модифицированными полипептидами |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
MX2016012314A (es) | 2014-03-25 | 2016-11-30 | Lanthiopep Bv | Analagos de apelina ciclicos. |
GB201407532D0 (en) * | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
JP6721572B2 (ja) | 2014-05-23 | 2020-07-15 | ノバルティス アーゲー | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 |
CN112851790A (zh) | 2014-06-23 | 2021-05-28 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
KR20170103970A (ko) | 2015-01-23 | 2017-09-13 | 노파르티스 아게 | 개선된 반감기를 갖는 합성 아펠린 지방산 접합체 |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
USD790683S1 (en) * | 2015-03-11 | 2017-06-27 | Resmed Limited | Pressurized air delivery console |
WO2016151018A1 (en) * | 2015-03-24 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
SI3300500T1 (sl) | 2015-05-20 | 2020-07-31 | Amgen Inc. | Triazolni agonisti receptorja APJ |
EP3416688B1 (en) | 2016-02-15 | 2022-08-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Apelin for use in the treatment of post-operative cognitive dysfunction |
US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
WO2018075822A1 (en) | 2016-10-19 | 2018-04-26 | Avive, Inc. | Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases |
US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
US11400247B2 (en) | 2016-12-22 | 2022-08-02 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
SG11201909879QA (en) | 2017-04-23 | 2019-11-28 | Fisher & Paykel Healthcare Ltd | Breathing assistance apparatus |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
CN113227093A (zh) | 2018-11-14 | 2021-08-06 | 阿尔塔万特科学公司 | 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法 |
ES2957324T3 (es) * | 2019-02-27 | 2024-01-17 | Air Liquide | Dispositivo de suministro de gas con bolsa deformable y sensores de presión diferencial |
CN112007027B (zh) * | 2020-09-14 | 2022-07-15 | 长春金赛药业有限责任公司 | 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0630405T3 (da) | 1992-11-17 | 1999-01-04 | Icos Corp | Hidtil ukendt 7-transmembranreceptor benævnt V28 |
GB2281513B (en) * | 1993-08-31 | 1997-12-03 | Ulco Eng Pty Ltd | Ventilator disconnect alarm |
EP0645119A3 (en) * | 1993-09-27 | 1998-04-15 | Ohmeda Inc. | Disabling apnoea volume software |
US5598838A (en) * | 1995-04-07 | 1997-02-04 | Healthdyne Technologies, Inc. | Pressure support ventilatory assist system |
CA2222830C (en) * | 1996-12-02 | 2004-03-30 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
CA2313246A1 (en) | 1997-12-24 | 1999-07-08 | Takeda Chemical Industries, Ltd. | Polypeptide, their production and use |
AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
ATE440857T1 (de) | 1998-10-05 | 2009-09-15 | Takeda Pharmaceutical | Verfahren zum eliminieren von n-terminalem methionin |
US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
EP1270585B1 (en) | 2000-03-23 | 2006-05-17 | Takeda Chemical Industries, Ltd. | Peptide derivative |
WO2001090123A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
US6349724B1 (en) * | 2000-07-05 | 2002-02-26 | Compumedics Sleep Pty. Ltd. | Dual-pressure blower for positive air pressure device |
US7574368B2 (en) * | 2000-12-15 | 2009-08-11 | Ric Investments, Llc | System and method for upgrading a pressure generating system |
CA2453434C (en) | 2001-07-16 | 2009-04-14 | Hk Pharmaceuticals, Inc. | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
US7157035B2 (en) * | 2001-12-14 | 2007-01-02 | Fisher & Paykel Healthcare Limited | Method of forming a respiratory conduit |
TW545624U (en) * | 2002-01-18 | 2003-08-01 | Enermax Technology Corp | Computer environment temperature/rotation speed display and self-adjusted fan speed device |
WO2003063892A1 (fr) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Utilisation d'apeline |
US7086399B2 (en) * | 2002-05-29 | 2006-08-08 | Fisher & Paykel Healthcare Limited | Apparatus for delivery of humidified gases therapy, associated methods and analysis tools |
US7736646B2 (en) | 2003-03-12 | 2010-06-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis with apelin compositions |
US20050152836A1 (en) | 2003-05-22 | 2005-07-14 | Euan Ashley | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
CN101035756A (zh) | 2004-06-17 | 2007-09-12 | 南卡罗来纳州医科大学研究发展基金会 | 非天然氨基酸 |
US20060045880A1 (en) | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
US20110097710A1 (en) | 2004-10-26 | 2011-04-28 | Macrae Calum A | Methods for detecting atrial fibrillation and related conditions |
US20060159676A1 (en) | 2005-01-14 | 2006-07-20 | Krieg Paul A | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
WO2007123233A1 (ja) | 2006-04-25 | 2007-11-01 | Kyushu University, National University Corporation | 動脈硬化性疾患関連遺伝子、およびその利用 |
CA2698824A1 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
NZ592738A (en) | 2008-11-04 | 2013-01-25 | Anchor Therapeutics Inc | APJ receptor compounds attached to a lipophilic tether through a carbonyl linker |
WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
EP2496243A2 (en) | 2009-11-04 | 2012-09-12 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
CN104254540A (zh) | 2012-01-09 | 2014-12-31 | 安科治疗公司 | Apj受体化合物 |
JP6505692B2 (ja) | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
SG11201600208RA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
EP3024846A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
-
2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en active Active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en active Active
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh active Active
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/xx unknown
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko active IP Right Grant
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 CA CA2862240A patent/CA2862240A1/en active Pending
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja active Active
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/en active Application Filing
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active Application Discontinuation
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/en active Active
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Application Discontinuation
-
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
-
2015
- 2015-01-28 HK HK15100964.5A patent/HK1200470A1/xx not_active IP Right Cessation
- 2015-05-18 US US14/714,914 patent/US9982017B2/en active Active
-
2017
- 2017-05-01 US US15/583,408 patent/US20170232221A1/en not_active Abandoned
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja active Active
-
2018
- 2018-05-22 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120239T1 (el) | Συνθετικα μιμητικα απελινης για την θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας | |
CU20160013A7 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca | |
EA201690282A1 (ru) | Биоконъюгаты синтетических апелиновых полипептидов | |
CY1125290T1 (el) | Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα | |
CY1120172T1 (el) | Αναστολεις κινασων σερινης/θρεονινης | |
BRPI1013409A2 (pt) | células de tecido de cordão umbilical humano como terapia para doença de alzheimer | |
BR112013005125A2 (pt) | deuterados análogos dos pridopidine úteis como estabilizadores dopaminérgicos | |
CU20140043A7 (es) | Benzilindazoles sustituidos como inhibidores de la quinasa bub1 | |
HN2010002250A (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos | |
DOP2015000012A (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
CR20120203A (es) | Derivados de ácido carboxílico cíclico sustituidos con acilamino y su uso como productos farmacéuticos | |
BRPI1013872A2 (pt) | formulações de citrato de cálcio e lactato de cálcio para alteração de propriedades biofísicas do revestimento da mucosa | |
EA201100483A1 (ru) | Новые пирролидин-2-оны в качестве hdm2 лигандов | |
BR112014013140A2 (pt) | cosmética de prótese | |
BRPI1014595A2 (pt) | procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer | |
CU20110209A7 (es) | Composiciones adecuadas para el tratamiento tópico o infecciones fúngicas de la piel y unas | |
UY38986A (es) | Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas | |
ES2535498T8 (es) | Alfa derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento | |
RU2011144281A (ru) | Способ остеосинтеза аппаратом орто-сув при деформациях среднего отдела стопы | |
NZ608729A (en) | 1,2,4-triazolone derivative | |
CY1124534T1 (el) | Διαταξεις για την αγωγη δερματικων βλαβων | |
EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
AR077427A1 (es) | Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st | |
IN2014DN08487A (el) | ||
AR096980A1 (es) | Polipéptidos cíclicos para el tratamiento de insuficiencia cardiaca |